Life Science Company News

Reset
Results 341 - 360 out of 500 displayed.
«  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17 18  19  20  21  22  23  24  25 »

Skye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting

Read more ››
By: GlobeNewswire - 30 Apr 2024
Related companies:  Skye Bioscience, Inc.

Gritstone bio Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA (samRNA) COVID-19 Vaccine at ESCMID Global 2024

Read more ››
By: GlobeNewswire - 30 Apr 2024
Related companies:  Gritstone bio, Inc.

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

Read more ››
By: GlobeNewswire - 30 Apr 2024
Related companies:  ProMIS Neurosciences, Inc.

Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

Read more ››
By: GlobeNewswire - 30 Apr 2024
Related companies:  Eton Pharmaceuticals, Inc.

ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab

Read more ››
By: GlobeNewswire - 30 Apr 2024
Related companies:  ASLAN Pharmaceuticals Ltd.

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)

Read more ››
By: GlobeNewswire - 30 Apr 2024
Related companies:  OKYO Pharma Limited

Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Read more ››
By: GlobeNewswire - 30 Apr 2024
Related companies:  Cyclacel Pharmaceuticals, Inc.

Vitestro Secures $22 Million (€20 million) for Autonomous Blood Draw Device

Read more ››
By: GlobeNewswire - 30 Apr 2024
Related companies:  Vitestro BV

CHARM Therapeutics appoints Dr Nicholas Edmunds as Chief Development Officer, Head of Pre-Clinical Development

Read more ››
By: GlobeNewswire - 30 Apr 2024
Related companies:  CHARM Therapeutics Limited

Replay and MD Anderson announce FDA clearance of IND application for first-in-class PRAME-targeted T-Cell Receptor Natural Killer (TCR-NK) cell therapy for hematological malignancies

Read more ››
By: GlobeNewswire - 30 Apr 2024

Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy

Read more ››
By: GlobeNewswire - 30 Apr 2024
Related companies:  Harmony Biosciences

Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024

Read more ››
By: GlobeNewswire - 30 Apr 2024
Related companies:  Clearside Biomedical, Inc.

SOPHiA GENETICS to Present at the 2024 RBC Capital Markets Global Healthcare Conference

Read more ››
By: GlobeNewswire - 30 Apr 2024
Related companies:  SOPHiA GENETICS, Inc.

Entourage Health Reports Fiscal Year 2023 Financial Results and Posts $54 Million in Total Revenues

Read more ››
By: GlobeNewswire - 30 Apr 2024

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report

Read more ››
By: GlobeNewswire - 30 Apr 2024

InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024

Read more ››
By: GlobeNewswire - 30 Apr 2024
Related companies:  InflaRx N.V.

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Read more ››
By: GlobeNewswire - 30 Apr 2024
Related companies:  Tenax Therapeutics Inc.

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts

Read more ››
By: GlobeNewswire - 30 Apr 2024
Related companies:  Daré Bioscience, Inc.

XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%

Read more ››
By: GlobeNewswire - 30 Apr 2024
Related companies:  XOMA Corporation

Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position

Read more ››
By: GlobeNewswire - 30 Apr 2024
Related companies:  Invivyd, Inc.
Results 341 - 360 out of 500 displayed.
«  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17 18  19  20  21  22  23  24  25 »

Enhance your business development with Biotechgate
Try for free »